On November 28, 2023 Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, reported the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, taking place in San Diego, California, from December 9-12, 2023 (Press release, Evaxion Biotech, NOV 28, 2023, View Source [SID1234638006]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Selected for an Oral Presentation – Evaxion has been chosen for an oral presentation from a competitive pool of >5000 submitted abstracts. The presentation will unveil a breakthrough achievement using the Company’s proprietary AI target discovery and development platform, AI-Immunology. Based upon a novel source of targets, endogenous retroviruses (ERVs), combined with unique data insights, Evaxion has discovered a novel concept for precision vaccines in hematological malignancies and selected solid cancers.
Tailored Precision Vaccines – The precision vaccines are tailored to the specific tumor profiles and immune systems of patient groups. This marks a significant stride forward in addressing the complexities of cancers, including hematological malignancies. The discovery will potentially allow for a broader than previously expected application of vaccines in cancer therapy.
Event Details:
Title: "Endogenous Retroviral Elements Constitute a Promising Vaccine Antigen Source for Hematological Malignancies"
Talk: 243
Session: Emerging Tools, Techniques and Artificial Intelligence in Hematology: Emerging Technologies for Understanding Benign and Malignant Hematology
Session: 803
Location: Room 30 – San Diego Convention Center
Time: Saturday, December 9, 2:30 p.m. PDT
Presenter: Anders Bundgård Sørensen, Project Director of Research and Discovery
About ERVs
Endogenous retroviruses (ERVs) are remnants of ancient viruses incorporated into the human genome. While dormant in normal cells due to strict epigenetic control, cancer cells may express these traces, making ERVs ideal targets for cancer vaccines.